Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Global X Copper Miners ETF (COPX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Global X Copper Miners ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288 (market cap $39.89B), while Global X Copper Miners ETF trades at $74.11. The key difference: Global X Copper Miners ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | COPX | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $491.22 | $95.70 |
52-Week Low | $278.09 | $42.75 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
COPX, the Global X Copper Miners ETF, trades at $76.54, up 1.51% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF provides diversified exposure to copper mining companies, capitalizing on structural demand from AI data centers and electrification. Recent news highlights copper's critical role in the AI boom, though supply constraints and market fragility pose challenges. A dividend of $0.26 is scheduled for July 2026.
The long-term outlook for COPX is supported by strong copper demand drivers, but near-term technical weakness and speculative volatility present risks. Investment appeal hinges on the execution of the electrification theme and miners' ability to overcome supply bottlenecks. Analyst sentiment remains cautiously optimistic given copper's fundamental tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →
